Despite denying any wrongdoing, Hikma joins a group of companies that have agreed to pay big settlements for their alleged respective roles in the ongoing opioid epidemic in the US.
As the US continues to battle the opioid crisis, Hikma Pharmaceuticals has announced a $150m multi-state settlement to resolve opioid-related cases that were brought up by the US government against the UK-based firm.
If all conditions are satisfied, Hikma will pay up to $115m in cash and $35m in donations of Hikma’s naloxone....
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
